Foundation Medicine and Collaborators to Present New Data at the American Society of Hematology (ASH) Annual Meeting that Supports Use of FoundationOne®Heme to Advance Personalized Medicine in Blood Cancers
Foundation Medicine and Collaborators to Present New Data at the American Society of Hematology (ASH) Annual Meeting that Supports Use of FoundationOne®Heme to Advance Personalized Medicine in Blood Cancers
-- New data demonstrate the value of comprehensive genomic profiling for informing clinical care and guiding use of targeted therapies, autologous stem cell transplantation and immunotherapy --
"Comprehensive genomic profiling (CGP) is proving to be an essential
component for personalized cancer care, particularly as we learn more
about the diverse genomic alterations in blood cancers," said
Cancer immunotherapy is emerging as a therapeutic tool for patients with diverse hematologic malignancies. New results to be presented at ASH using FoundationOneHeme show that more than one-quarter of patients with PCL had high tumor mutational burden (TMB), a genomic biomarker that has been shown across several cancer types to predict response to immuno-oncology treatment strategies, such as checkpoint inhibitors. Less than 50 percent of PCL patients achieve complete remission with current standard of care treatments, underscoring a need for new treatment options for these patients.
New results also support the role of FoundationOneHeme to guide therapy selection and predict response to treatment. In an oral study to be presented, FoundationOneHeme detected NTRK fusions in a wide variety of hematologic malignancies, and clinical response to a TRK inhibitor was subsequently observed in a patient with refractory AML and an ETV6-NTRK2 fusion. In another study to be presented, CGP offered insights that may facilitate risk-adapted clinical management decisions in patients with intermediate-and favorable-risk AML, potentially informing optimal use of autologous stem cell transplantation (auto-SCT) over conventional consolidation chemotherapy. For example, the study showed the presence of PTPN11 mutations to predict long term clinical outcomes following an auto-SCT.
Other results to be presented at ASH demonstrate the ability of FoundationOneHeme to detect both known and novel BCL6 rearrangements in NHL, including cases that previously tested negative with standard-of-care single marker testing. BCL6 rearrangements have known diagnostic and prognostic utility in specific subtypes of NHL.
-
115 - Unrecognized clonal hematopoiesis of indeterminate
potential in solid tumors: Implications for interpretation of
molecular testing,
Dec 9 ,9:30am , C208-210 (Oral Presentation) -
1423 - The role of comprehensive mutational profiling in
predicting patients who may benefit from autologous hematopoietic cell
transplant for acute myeloid leukemia,
Dec 9 ,5:30pm-7:30pm , Hall A2 (Poster Presentation) -
1657 - A distinct mutation profile might contribute to the
dismal outcome of triple negative patients with primary myelofibrosis,
Dec 9 ,5:30pm-7:30pm , Hall A2 (Poster Presentation)
-
417 - Comprehensive genomic profiling identifies novel BCL6
rearrangements in diverse subtypes of Non-Hodgkin lymphoma as well as
known rearrangements not detected using standard of care assays,
Dec 10 ,12:30pm ,Marcus Auditorium (Oral Presentation) -
476 - Comprehensive genomic profiling identifies genomic
alterations that define
Philadelphia -like B-acute lymphoblastic leukemia,Dec 10 ,4:45pm , B213-B214 (Oral Presentation)
-
794 - Characterization of NTRK fusions and therapeutic
response to NTRK inhibition in hematologic malignancies,
Dec 11 ,4:45pm , B207-208 (Oral Presentation) -
3800 - Recurrent copy number variants are highly prevalent in
acute myeloid leukemia,
Dec 11 ,6:00pm-8:00pm , Hall A2 (Poster Presentation) -
3996 - Comprehensive genomic profiling demonstrates differences
in primary CNS lymphoma and systemic diffuse large B cell lymphoma and
reveals biomarkers indicating potential benefit from immune checkpoint
inhibitors,
Dec 11 ,6:00pm-8:00pm , Hall A2 (Poster Presentation) -
4016 - Next generation sequencing of Castleman disease and
follicular dendritic cell sarcomas associated with Castleman disease,
Dec 11 ,6:00pm-8:00pm , Hall A2 (Poster Presentation)
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the value of
comprehensive genomic profiling utilizing FoundationOneHeme for
informing clinical care, guiding the use of targeted therapy or
immunotherapy, advancing personalized medicine, and addressing unmet
medical needs across a wide range of hematologic malignancies; and the
ability of FoundationOneHeme to predict treatment response and detect
certain genomic alterations. All such forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include the risk that the results presented are found to
lack scientific, medical or clinical merit or utility; that subsequent
research renders the results presented less useful or not useful in
clinical practice;
View source version on businesswire.com: http://www.businesswire.com/news/home/20171206005062/en/
Media Contact:
pr@foundationmedicine.com
or
Investor
Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media